Medtronic, Inc. (MDT) PT Raised to $94 at Barclays

Medtronic, Inc. (MDT) PT Raised to $99 at Jefferies; Q2 Eases Growth Concerns

Jefferies raised its price target on Medtronic, Inc. (NYSE: MDT) to $99.00 (from $96.00) while maintaining a Buy rating following Q2 results.

Analyst Raj Denhoy said the results eased concerns of a slowing growth trajectory.

"Despite weather impacts, F18 guidance for +4-5% sales and... More

Medtronic, Inc. (MDT) PT Raised to $86 at Wells Fargo on 2Q Report; 'Better gross Margin Than Modeled'

Wells Fargo raised its price target on Medtronic, Inc. (NYSE: MDT) to $86.00 (from $83.00) while maintaining a Market Perform rating, following the company's second quarter earnings report.

Analyst Larry Biegelsen notes a positive outlook on the shares, as the company reported second quarter... More

Medtronic, Inc. (MDT) PT Raised to $88 at Leerink Partners, Gorwth Should Accelerate in H2 2018

Leerink Partners raised its price target on Medtronic, Inc. (NYSE: MDT) to $88.00 (from $85.00) while maintaining a Market Perform rating.

Medtronic, Inc. (MDT) PT Raised to $85 at Stifel

Stifel raised its price target on Medtronic, Inc. (NYSE: MDT) to $85.00 (from $83.00) while maintaining a Hold rating.

Medtronic, Inc. (MDT) PT Bumped to $95 at Needham & Company

Needham & Company analyst Mike Matson bumped his price target on Medtronic, Inc. (NYSE: MDT) to $95.00 (from $94.00) while maintaining a Buy rating following Q1 results that beat the Street and reiterated guidance.

Matson notes organic revenue growth improved to 4.0% (excluding Hurricane Maria)... More

Medtronic (MDT) Tops Q2 EPS by 8c, Reiterates Guidance

Medtronic (NYSE: MDT) reported Q2 EPS of $1.07, $0.08 better than the analyst estimate of $0.99. Revenue for the quarter came in at $7.1 billion versus the consensus estimate of $6.93 billion.

Guidance
Medtronic today reiterated its revenue and non-GAAP EPS guidance. The company's guidance is given on a comparable, constant currency basis, which accounts for the divestiture of certain businesses from its prior period Patient Monitoring & Recovery division by removing the financial impact... More